Dr. Nicky Whiffin: Getting to know Rosetrees researchers

Dr. Nicky Whiffin: Getting to know Rosetrees researchers

Rosetrees researcher profile: Dr. Nicky Whiffin, Imperial College London

Who Rosetrees Trust is funding

Dr. Nicky Whiffin is a research fellow in the National Heart and Lung Institute, at Imperial College London. Her research focuses on exploring genetic variants that cause rare diseases. Although individually rare, these diseases collectively affect >250 million people worldwide. Genetic testing is widespread in the clinical management of rare diseases, but current strategies only find a genetic cause for ~50% of cases.

Nicky is part of the Cardiovascular Genetics and Genomics team at Imperial College, led by her fellowship sponsor Dr. James Ware. The group focuses on a specific class of rare diseases called inherited cardiomyopathies. These conditions are diseases of the heart muscle, resulting in heart failure and often sudden death.

To date, much of genetic research into rare disease has focused on regions of the DNA that code directly for proteins, which accounts for ~1.5% of the genome, and these regions have been the traditional focus in clinical diagnostic settings. This is because studies of ‘non-coding’ DNA, rich in functional elements that regulate protein production, have certain limitations including the requirement for large sample sizes, and difficulties in interpreting the effect of any individual variant. Despite these challenges, there is strong supporting evidence indicating that variants in non-coding DNA cause disease.

Nicky is using state-of-the-art techniques to narrow down the 98.5% of the genome that is non-coding to identify small regions and individual variants that cause rare diseases. The data output from this project will enable investigation of the contribution of rare non-coding variants to the pathogenesis of rare diseases, including cardiomyopathies. Nicky’s research is also highly translational, because it will inform genetic testing and impact patient care.

Nicky said: To a patient with a rare disease, knowing the precise genetic cause is invaluable. This genetic diagnosis can be used to screen other family members to identify those also at risk of disease, to suggest personalised treatment approaches and can often end a long ‘diagnostic odyssey’ for patients and their families. This research is increasing our understanding of non-coding variants that cause rare diseases and how they do so. Ultimately this will enable more patients to receive a valuable genetic diagnosis.

Dr. Nicky Whiffin

How Rosetrees Trust have supported Dr. Nicky Whiffin

Nicky is a Rosetrees/Stoneygate 2018 Imperial College Research Fellow, receiving funding for her fellowship from 2018 to 2022, under the sponsorship of Dr. James Ware. This springboard award has enabled Nicky to build her independent research program and foster a strong collaboration with Dr. Daniel MacArthur and researchers at the Broad Institute in Boston where she is a visiting scientist.

What the outcomes are of Rosetrees Trust-/Stoneygate-funded research from Dr. Nicky Whiffin

Nicky is a member of the analysis team of the Genome Aggregation Database (gnomAD), a collaboration of >100 principle investigators spearheaded by Dr. MacArthur. GnomAD is used across the globe, by both researchers and for clinical diagnostics, and is central to the analysis for this project.

Briefly, gnomAD is a population reference dataset that brings together exome and genome sequencing data from largescale sequencing projects, accessible to the wider scientific community. The resource gives us an accurate picture of which genetic variants exist naturally in the population, helping us to identify those which are unlikely to cause rare diseases. Nicky and James are members of the gnomAD consortium, contributing to the creation and analysis of the data. This database is continuously being scaled-up, growing from sequencing data of ~60,000 individuals (as the precursor ExAC database) to more than 140,000 individuals (~15,000 whole-genomes). The latest release contains whole-genome sequencing data for >70,000 individuals.

Today, the gnomAD consortium released a package of 7 publications in Nature Journals (Whiffin et al., 2020a; Whiffin et al., 2020b; Karczewski et al., 2020; Collins et al., 2020; Cummings et al., 2020; Wang et al., 2020; Minikel et al., 2020). Nicky led the analysis for two of the papers, published in Nature Communications (Whiffin et al., 2020a) and Nature Medicine (Whiffin et al., 2020b).

In the first of these, Nicky, supported by James and Dr. MacArthur, used the whole-genome sequenced subset of gnomAD to identify and characterise a new class of variants, found outside of protein coding regions, that reduce protein translation and lead to rare disease, published in Nature Communications (Whiffin et al., 2020a). Here, the team demonstrated the power of using large population datasets to identify specific non-coding bases that are under strong selection, using an approach that had previously only been applied to protein-coding variants. When this research was first published on the pre-print sever bioRxiv, Nicky was approached by others in the community who had determined new genetic diagnoses for previously unsolved patients as a direct result of this work.

The second of these papers, published in Nature Medicine (Whiffin et al., 2020b), is a large collaboration between the gnomAD consortium and the direct-to-consumer genetic testing company 23andMe, which also uses the UK Biobank resource. This work was co-led by Irina Armean from the Broad Institute and Aaron Kleinman from 23andMe. Together, they looked specifically at loss-of-function variants in the gene LRRK2. Variants that cause increased LRRK2 kinase function are a known cause of Parkinson’s disease, and drug companies are currently developing LRRK2 inhibitors as a potential treatment strategy. In early model organism studies, however, completely knocking-out LRRK2 resulted in severe side-effects in the lung/liver/kidney. Here, the team looked directly in over 4 million humans, from their three datasets. They assessed the phenotypic impact of a lifelong natural reduction in LRRK2 protein levels, caused by heterozygous loss-of-function variants. The team found no detectable increase in severe disease phenotypes in individuals with these variants, suggesting that reducing LRRK2 protein levels in humans should not cause any severe disease side-effects, at least due to on-target effects. This is promising news for patients with Parkinson’s disease.

What the future holds for Dr. Nicky Whiffin

Nicky has recently been awarded a prestigious Sir Henry Dale fellowship from the Wellcome Trust. Moving from Imperial to the Wellcome Centre for Human Genetics at the University of Oxford, Nicky will become a group leader and continue her research exploring the effect of non-coding variants in rare diseases.

Written by: Dr. Rebecca Downing and Dr. Nicky Whiffin

John Samuels, Medical Research Consultant and familiar face at the Rosetrees Trust, retires

John Samuels, Medical Research Consultant and familiar face at the Rosetrees Trust, retires

After 25 years of meeting our researchers from across the UK, and offering that personal touch from the Rosetrees Trust, John Samuels is now retired. John’s dedication to his role as Medical Research Consultant has seen him attend hundreds of researcher meetings over the years, which has also ensured that the Rosetrees Trust continues to support the best in medical research.

The Rosetrees Trust Team, at the Richard Ross Inaugural Lecture

John’s knowledge and approach has been passed to all members of the Rosetrees Trust team. We will be maintaining our personal touch with all of our researchers, and our community.

John’s retirement lunch, joined by family and friends
Richard and John

Some of John’s other passions in life are travel, art, and wine. He hopes to use his retirement to further explore these with his wife. He will remain in close contact with the Rosetrees Trust team, and keep in touch with the researchers that he has met over the years. We wish John well for the future.

John’s delicious Rosetrees Trust cake made by Sheree
Emergency COVID-19 ultrasensitive point of care diagnostic

Emergency COVID-19 ultrasensitive point of care diagnostic

Professor Molly Stevens, a member of our Scientific Advisory Panel and a Rosetrees Trust-funded researcher, has recently received more than €600,000 in funding for a project that aims to develop an emergency COVID-19 ultrasensitive point of care diagnostic. This project is being supported by the Rosetrees Trust, as well as two other funding sources. These are the EU’s European Institute of Innovation and Technology, where Molly’s team was the only UK-based group to receive funding from EIT Health in its Rapid Response initiative, and Imperial’s COVID-19 Response Fund.

Professor Molly Stevens elected as FRS

Professor Molly Stevens elected as FRS

Delighted to announce that a member of our Scientific Advisory Panel, Professor Molly Stevens, was recently elected as a Fellow of the Royal Society, amongst 60 exceptional scientists from around the world. Professor Molly Stevens has been honoured for ground-breaking advances in the engineering of bio-inspired materials for regenerative medicine and biosensing.

Molly has received Rosetrees Trust funding since 2009, and we are very proud to support her innovative and highly translational research.

Professor Helen Fletcher and Hannah Painter: Getting to know Rosetrees researchers

Professor Helen Fletcher and Hannah Painter: Getting to know Rosetrees researchers

Rosetrees researcher profile: Professor Helen Fletcher and Hannah Painter, London School of Hygiene and Tropical Medicine

Who Rosetrees Trust is funding

Tuberculosis (TB) is a leading cause of death from a single infectious agent. In 2018, 1.5 million deaths were reported and 10 million individuals developed TB active disease. This high mortality rate is largely due to the complexities of diagnosis and access to quality care for many. Multi- and extensively-drug-resistant TB remains a great global concern. The Bacille Calmette-Guérin (BCG) vaccine is currently the only clinically approved vaccine against TB. The vaccine provides some protection against severe forms of TB in children; however, protection against pulmonary TB in adults varies dramatically (between 0 and 80%). Despite recent breakthroughs in the TB vaccine pipeline, development and validation of TB vaccines remains slow, and understanding of the host immune response to Mycobacterium tuberculosis (Mtb), the causative agent of TB, remains poor. Extensive preclinical evaluation of candidate TB vaccines is a time-consuming and expensive process. To this end, TB vaccines are typically tested against laboratory strains of Mtb, despite reported variations in response to infection with different clinical isolates of Mtb in animal models.

Professor Helen Fletcher’s research at London School of Hygiene and Tropical Medicine focuses on TB vaccines and immune correlates of risk. In a recent review in Seminars in Immunology, Professor Fletcher highlights the growing interest in whole systems approaches to the identification of correlates of protection and progression to TB disease.

This project aims to accelerate the development of effective vaccines for protection against Mtb.

Hannah Painter said: “Tools which enable in-depth analysis of vaccine efficacy, as well as the underlying immune mechanisms associated with vaccination, are urgently required to improve and inform the TB vaccine pipeline.”

Professor Helen Fletcher and Hannah Painter

How Rosetrees Trust have supported Professor Helen Fletcher and Hannah Painter


Professor Helen Fletcher received Rosetrees Trust funding in 2016, to support Hannah Painter’s PhD which is due to complete later this year.

What the outcomes are of Rosetrees Trust-funded research from Professor Helen Fletcher and Hannah Painter


Professor Helen Fletcher and Hannah Painter have been successful in developing an ex vivo method to evaluate the efficacy of vaccines against diverse clinical isolates of Mtb in the mouse model. The use of the mycobacterial growth inhibition assay (MGIA) as a preclinical method to assess vaccine-induced protection was previously established in mouse spleen cells. The assay aims to provide a shorter and cheaper method of testing potential vaccine efficacy, generating data which may aid the design of traditional animal infection studies in a more cost-effective and informed manner.

The current work, published in Scientific Reports, has optimised the MGIA for use in both lung and spleen and streamlined the capacity of the assay for head-to-head testing of multiple Mtb strains or vaccines.

In addition, where variations in vaccine efficacy have been observed in the MGIA, flow cytometry and RNA-seq analysis have been performed to gain further insight into the mechanisms behind these observations.

Rosetrees Trust support on this project has helped the team secure further grants, including an MRC-BBSRC VALIDATE Pump Prime award, and an MRC National Productivity Fund placement award. Furthermore, this grant has supported PhD student, Hannah Painter, who has secured funding to continue to work on this project.

Written by: Dr. Rebecca Downing, Professor Helen Fletcher and Hannah Painter

COVID-19

COVID-19

We hope that our community of researchers and partners are keeping well at this difficult time.

We encourage all our researchers to get in touch and share their plans with us. We want to continue supporting our projects where we can and we would ask you to respond to project update requests with as much information as possible so that we can make decisions without delay.

Keep well and we look forward to the entire research community returning to work and identifying answers to important questions.